Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06559150 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
A Phase 2 study of Non-cystic Fibrosis Bronchiectasis, sponsored by Verona Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT06559150: Recruiting Phase 2 study of Non-cystic Fibrosis Bronchiectasis, sponsored by Verona Pharma.
NCT06559150 is a Phase 2 study of Non-cystic Fibrosis Bronchiectasis that is actively recruiting participants, run by Verona Pharma. The registered enrollment target is 180 participants, above the 66-participant average among 3 other Non-cystic Fibrosis Bronchiectasis trials with a reported enrollment target (173% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06559150, a Phase 2 study of Non-cystic Fibrosis Bronchiectasis, is actively recruiting participants, sponsored by Verona Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).
Conditions Studied
Interventions
- DRUG Nebulized Ensifentrine Suspension; 3 mg
- DRUG Nebulized Placebo Solution
Study Locations (20)
North Carolina
- University of North Carolina - Chapel Hill
- Accellacare of Wilmington - Wilmington
- Southeastern Research Center - Winston-Salem
California
- So Cal Institute for Respiratory Diseases, Inc. - Los Angeles
- University of California Davis Medical Center - Sacramento
Georgia
- Emory University at Saint Joseph Pulmonary Clinic - Atlanta
- Augusta University - Augusta
Alabama
- Kirklin Clinic of UAB Hospital - Birmingham
Colorado
- National Jewish Health Main Campus - Denver
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Florida
- University of Miami - Miami
Indiana
- ASHA Clinical Research - Hammond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2024-09-11 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What NCT06559150 shows while recruiting
NCT06559150 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 66-participant average among 3 other Non-cystic Fibrosis Bronchiectasis trials with a reported enrollment target (173% higher).
The record links to 1 condition, with Non-cystic Fibrosis Bronchiectasis appearing as the primary indexed condition, and to 2 interventions - of which Nebulized Ensifentrine Suspension; 3 mg is the first listed.
NCT06559150 names 20 study sites across 16 states, led by North Carolina, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT06559150 about?
NCT06559150 is a clinical study titled "A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis". This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis...
What is the current status of trial NCT06559150?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2024-09-11. Estimated completion is 2026-09.
What conditions does trial NCT06559150 study?
This clinical trial studies the following conditions: Non-cystic Fibrosis Bronchiectasis.
What interventions are being tested in trial NCT06559150?
The interventions under investigation include: Nebulized Ensifentrine Suspension; 3 mg (DRUG), Nebulized Placebo Solution (DRUG).
Who is sponsoring clinical trial NCT06559150?
This trial is sponsored by Verona Pharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06559150 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-cystic Fibrosis Bronchiectasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI